There are two ways in which IXA can provide funding for start-up or early stage companies:
The Proof of Concept and Preseed Fund, managed and administrated by IXA, has been established to stimulate research-driven entrepreneurship among staff and students of the five IXA partners and to create an environment where new initiatives and ideas can be tested and further developed.
A Preseed Loan provides starting entrepreneurs with the financial means to found and/or further develop a new company.
The Preseed Fund caters to start-up, which can be:
A condition for Preseed funding is that the funding will be either for an invention by one of the five institutions, or for initiating a joint research project with one of the institutions.
Proof of Concept (POC) funding enables (aspiring) entrepreneurs to undertake a technical feasbility study for their concept, invention or idea.
Start- up companies, SMEs (natural person or companies) and societal organisations (excluding educational and research institutions) can apply for POC funding.
A condition for POC funding is that the funding will be either for an invention by one of the five institutions, or for initiating a joint research project with one of the institutions.
Teachers from the department of medical informatics of Amsterdam UMC have developed an online platform to gather and visualize structured curriculum information, called act-E. Education managers, teachers and students use this platform to gain insights regarding their curricula that could never be viewed as easily before. These insights help them to have an informed conversation […]News
VU alumni International Business Administration Michael Musandu and Ugnius Rimsa founded Lalaland in 2019. The startup generates and hyper personalizes full human body models from head to toe by using AI. As a result, models are available in different ethnicities, sizes and ages, allowing customers to always recognize themselves in the clothing of their choice. […]News
Chronic kidney diseases are a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. Now, a monoclonal antibody, named BION-1301 (anti-APRIL), is being developed to treat patients with IgA nephropathy. BION-1301 is a potential disease-modifying approach to prevent the formation of […]News